Advertisement
YOU ARE HERE: LAT HomeCollectionsNeurontin Drug
IN THE NEWS

Neurontin Drug

FEATURED ARTICLES
BUSINESS
April 29, 2004 | From Reuters
Generic drug makers Teva Pharmaceutical Industries Ltd. and Alpharma Inc. said they agreed to share revenue from generic versions of Pfizer Inc.'s top-selling epilepsy drug, Neurontin. Alpharma would have a six-month U.S. generic exclusivity period for copycat capsules and perhaps for copycat tablets if generic drug makers win their court battles with Pfizer. Shares of Alpharma jumped $3.10 to $24 on the NYSE, while shares of Teva rose 40 cents to $66.17 on Nasdaq. From Reuters
ARTICLES BY DATE
BUSINESS
August 24, 2005 | From Bloomberg News
Generic-drug makers including Ivax Corp. and Teva Pharmaceutical Industries Ltd. aren't infringing patents on Pfizer Inc.'s epilepsy drug Neurontin by selling low-cost versions, a federal judge ruled. U.S. District Judge John Lifland in Newark, N.J., said the generic version of gabapentin, the key ingredient in Neurontin, didn't infringe. Pfizer will appeal, spokesman Paul Fitzhenry said. Teva, Ivax and Alpharma Inc.
Advertisement
BUSINESS
August 24, 2005 | From Bloomberg News
Generic-drug makers including Ivax Corp. and Teva Pharmaceutical Industries Ltd. aren't infringing patents on Pfizer Inc.'s epilepsy drug Neurontin by selling low-cost versions, a federal judge ruled. U.S. District Judge John Lifland in Newark, N.J., said the generic version of gabapentin, the key ingredient in Neurontin, didn't infringe. Pfizer will appeal, spokesman Paul Fitzhenry said. Teva, Ivax and Alpharma Inc.
BUSINESS
April 29, 2004 | From Reuters
Generic drug makers Teva Pharmaceutical Industries Ltd. and Alpharma Inc. said they agreed to share revenue from generic versions of Pfizer Inc.'s top-selling epilepsy drug, Neurontin. Alpharma would have a six-month U.S. generic exclusivity period for copycat capsules and perhaps for copycat tablets if generic drug makers win their court battles with Pfizer. Shares of Alpharma jumped $3.10 to $24 on the NYSE, while shares of Teva rose 40 cents to $66.17 on Nasdaq. From Reuters
Los Angeles Times Articles
|